Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NRIX logo NRIX
Upturn stock ratingUpturn stock rating
NRIX logo

Nurix Therapeutics Inc (NRIX)

Upturn stock ratingUpturn stock rating
$10.56
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: NRIX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

18 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $29.83

1 Year Target Price $29.83

Analysts Price Target For last 52 week
$29.83 Target price
52w Low $8.18
Current$10.56
52w High $29.56

Analysis of Past Performance

Type Stock
Historic Profit -25.14%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 807.31M USD
Price to earnings Ratio -
1Y Target Price 29.83
Price to earnings Ratio -
1Y Target Price 29.83
Volume (30-day avg) 18
Beta 2.15
52 Weeks Range 8.18 - 29.56
Updated Date 08/15/2025
52 Weeks Range 8.18 - 29.56
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.6

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -234.57%
Operating Margin (TTM) -109.68%

Management Effectiveness

Return on Assets (TTM) -26.13%
Return on Equity (TTM) -50.67%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 373455188
Price to Sales(TTM) 9.13
Enterprise Value 373455188
Price to Sales(TTM) 9.13
Enterprise Value to Revenue 4.23
Enterprise Value to EBITDA -3.35
Shares Outstanding 76449400
Shares Floating 57946318
Shares Outstanding 76449400
Shares Floating 57946318
Percent Insiders 1.43
Percent Institutions 110.98

ai summary icon Upturn AI SWOT

Nurix Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Nurix Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule therapies designed to modulate cellular protein levels to treat cancer and other diseases. Founded in 2009, the company has progressed through various stages of research and development, advancing multiple programs into clinical trials.

business area logo Core Business Areas

  • Drug Discovery & Development: Nurix focuses on identifying and developing small molecule therapies that target E3 ligases to modulate protein levels, thereby treating diseases like cancer and immune disorders.

leadership logo Leadership and Structure

The leadership team includes individuals with extensive experience in drug discovery, development, and commercialization. The organizational structure is typical of a biotechnology company, with research, development, and administrative functions.

Top Products and Market Share

overview logo Key Offerings

  • NX-2127: NX-2127 is a potent, oral BTK degrader in Phase 1 clinical trials for B-cell malignancies. Market share is currently 0 as it is pre-revenue. Competitors include BTK inhibitors such as Ibrutinib (Imbruvica), Acalabrutinib (Calquence), and Zanubrutinib (Brukinsa). There are other degrader drugs in clinical trials.
  • NX-1607: NX-1607 is a CBL-B inhibitor targeting tumor microenvironment. Market share is currently 0 as it is pre-revenue. Competitors are other investigational drugs targeting the tumor microenvironment.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, specifically in the oncology and immunology sectors, is highly competitive and rapidly evolving. There's a growing focus on targeted therapies and personalized medicine.

Positioning

Nurix is positioned as an innovative company utilizing targeted protein modulation to address unmet needs in cancer and immunology. Their competitive advantage lies in their unique platform targeting E3 ligases.

Total Addressable Market (TAM)

The total addressable market for cancer and immunology therapeutics is substantial, estimated to be hundreds of billions of dollars. Nurix's position depends on the clinical success and commercialization of its pipeline.

Upturn SWOT Analysis

Strengths

  • Novel drug discovery platform
  • Strong intellectual property portfolio
  • Experienced management team
  • Focus on high unmet medical needs

Weaknesses

  • Dependence on successful clinical trials
  • High cash burn rate
  • Limited commercialization experience
  • Reliance on funding

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline through new targets
  • Positive clinical trial results
  • Acquisition or licensing of complementary technologies

Threats

  • Clinical trial failures
  • Competition from established players
  • Regulatory hurdles
  • Patent challenges
  • Economic downturn affecting investment in biotech

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • MRK
  • ABBV
  • PFE

Competitive Landscape

Nurix faces significant competition from larger pharmaceutical companies with established oncology and immunology portfolios. Nurixu2019s novel approach using E3 ligases provides a potential differentiating factor, but it must demonstrate clinical efficacy.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been characterized by pipeline advancement rather than revenue generation.

Future Projections: Future growth depends on clinical trial outcomes and potential partnerships. Analyst estimates are not readily available for direct structured output.

Recent Initiatives: Recent initiatives include advancing NX-2127 and NX-1607 through clinical trials and exploring new E3 ligase targets.

Summary

Nurix Therapeutics is a development-stage biopharmaceutical company pioneering targeted protein modulation. Their innovative platform offers potential, but they face challenges including dependence on clinical trial success and significant competition. Positive clinical data and strategic partnerships are crucial for their long-term growth and success. The company needs to focus on securing financing to ensure continued operation.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Nurix Therapeutics Investor Relations
  • SEC Filings
  • Company Press Releases

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market conditions and company-specific events can significantly impact the company's performance. The AI rating is an estimate and should not be the sole basis for investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Nurix Therapeutics Inc

Exchange NASDAQ
Headquaters San Francisco, CA, United States
IPO Launch date 2020-07-24
CEO, President & Director Dr. Arthur T. Sands M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 286
Full time employees 286

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.